









市場行情
/
股票
/
nasdaq-mrk
/

Merck & Co Inc

MRK

106.850USD

+0.400+0.38%

收盤 12/26, 16:00（美東）報價延遲15分鐘

265.77B總市值

14.10本益比TTM



Merck & Co Inc

106.850

+0.400+0.38%

概覽公司財務分析

概覽

公司

財務

分析

關於 Merck & Co Inc 公司

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

Merck & Co Inc簡介



公司代碼MRK

公司名稱Merck & Co Inc

上市日期Feb 06, 2077

CEODavis (Robert M)

員工數量75000

證券類型Ordinary Share

年結日Feb 06

公司地址126 East Lincoln Avenue

城市RAHWAY

上市交易所NASDAQ OMX NASDAQ Basic NYSE

國家United States of America

郵編07065

電話19087404000

網址https://www.merck.com/

公司代碼MRK

上市日期Feb 06, 2077

CEODavis (Robert M)

Merck & Co Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

85.34K

+28.11%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

79.59K

+0.92%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

53.42K

+90.81%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

22.91K

+5.27%

Ms. Patricia F. Russo

Independent Director

13.15K

Mr. Thomas Henry (Tom) Glocer, J.D.

Lead Independent Director

5.10K

Mr. Inge G. Thulin

Independent Director

2.93K

Ms. Pamela J. Craig

Independent Director

1.72K

名稱

名稱/職務

職務

持股

持股變動

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

85.34K

+28.11%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

79.59K

+0.92%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

53.42K

+90.81%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

22.91K

+5.27%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Oncology-Keytruda

7.96B

50.34%

Vaccines -Gardasil/Gardasil

1.13B

7.12%

Animal Health-Livestock

961.00M

6.08%

Animal Health-Companion Animals

685.00M

4.33%

Vaccines -ProQuad/M-M-R II/Varivax

609.00M

3.85%

其他

4.47B

28.27%

地區USD

名稱

營收

佔比

United States

8.84B

55.90%

Europe, Middle East and Africa

3.66B

23.15%

Latin America

859.00M

5.43%

Asia Pacific (Other than China and Japan)

785.00M

4.97%

Japan

626.00M

3.96%

其他

1.04B

6.59%

業務

地區

業務USD

名稱

營收

佔比

Oncology-Keytruda

7.96B

50.34%

Vaccines -Gardasil/Gardasil

1.13B

7.12%

Animal Health-Livestock

961.00M

6.08%

Animal Health-Companion Animals

685.00M

4.33%

Vaccines -ProQuad/M-M-R II/Varivax

609.00M

3.85%

其他

4.47B

28.27%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.11%

BlackRock Institutional Trust Company, N.A.

5.69%

State Street Investment Management (US)

4.76%

Wellington Management Company, LLP

3.03%

Geode Capital Management, L.L.C.

2.41%

其他

74.00%

持股股東

佔比

The Vanguard Group, Inc.

10.11%

BlackRock Institutional Trust Company, N.A.

5.69%

State Street Investment Management (US)

4.76%

Wellington Management Company, LLP

3.03%

Geode Capital Management, L.L.C.

2.41%

其他

74.00%

股東類型

持股股東

佔比

Investment Advisor

42.31%

Investment Advisor/Hedge Fund

26.78%

Research Firm

3.18%

Pension Fund

2.51%

Bank and Trust

2.21%

Sovereign Wealth Fund

1.55%

Hedge Fund

1.06%

Insurance Company

0.69%

Family Office

0.13%

其他

19.59%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

5358

2.02B

81.35%

-45.75M

2025Q2

5398

2.02B

80.82%

-16.42M

2025Q1

5446

2.05B

81.47%

-3.32M

2024Q4

5410

2.04B

80.88%

+11.87M

2024Q3

5200

2.01B

79.47%

-7.96M

2024Q2

5181

2.01B

79.28%

-4.86M

2024Q1

5154

2.00B

78.88%

-6.10M

2023Q4

5065

1.99B

78.60%

+584.81K

2023Q3

4871

1.98B

78.17%

-32.03M

2023Q2

4864

2.00B

78.94%

-18.54M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

251.75M

10.08%

+356.59K

+0.14%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

142.78M

5.72%

-4.51M

-3.06%

Jun 30, 2025

State Street Investment Management (US)

118.49M

4.74%

-2.04M

-1.69%

Jun 30, 2025

Wellington Management Company, LLP

76.86M

3.08%

-4.81M

-5.89%

Jun 30, 2025

Geode Capital Management, L.L.C.

58.95M

2.36%

-704.59K

-1.18%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

53.87M

2.16%

+4.64M

+9.42%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

36.11M

1.45%

+1.13M

+3.23%

Jun 30, 2025

Fidelity Management & Research Company LLC

28.48M

1.14%

+229.47K

+0.81%

Jun 30, 2025

Fisher Investments

25.01M

+567.90K

+2.32%

Jun 30, 2025

BlackRock Asset Management Ireland Limited

22.79M

0.91%

+764.14K

+3.47%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

VanEck Pharmaceutical ETF

16.09%

FT Vest DJIA Dogs 10 Target Income ETF

10.79%

First Trust NASDAQ Pharmaceuticals ETF

7.94%

Invesco Dow Jones Industrial Average Dividend ETF

6.94%

First Trust Morningstar Dividend Leaders Index Fund

5.39%

Coastal Compass 100 ETF

5.13%

Invesco Pharmaceuticals ETF

4.96%

VanEck Morningstar Wide Moat Value ETF

4.73%

Vaneck Durable High Dividend ETF

4.65%

Franklin Income Focus ETF

4.56%

VanEck Pharmaceutical ETF

佔比16.09%

FT Vest DJIA Dogs 10 Target Income ETF

佔比10.79%

First Trust NASDAQ Pharmaceuticals ETF

佔比7.94%

Invesco Dow Jones Industrial Average Dividend ETF

佔比6.94%

First Trust Morningstar Dividend Leaders Index Fund

佔比5.39%

Coastal Compass 100 ETF

佔比5.13%

Invesco Pharmaceuticals ETF

佔比4.96%

VanEck Morningstar Wide Moat Value ETF

佔比4.73%

Vaneck Durable High Dividend ETF

佔比4.65%

Franklin Income Focus ETF

佔比4.56%

分紅派息



近5年累計派現 35.12B 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

Nov 18, 2025

MRK.NB Interim Cash Dividend of gross USD 0.85 paid on Jan 08, 2026 going ex on Dec 15, 2025

Dec 15, 2025

Jan 08, 2026

Dec 15, 2025

Jul 22, 2025

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Oct 07, 2025 going ex on Sep 15, 2025

Sep 15, 2025

Oct 07, 2025

Sep 15, 2025

May 27, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Jul 08, 2025 going ex on Jun 16, 2025

Jun 16, 2025

Jul 08, 2025

Jun 16, 2025

Jan 28, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025

Mar 17, 2025

Apr 07, 2025

Mar 17, 2025

Nov 19, 2024

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024

Dec 16, 2024

Jan 08, 2025

Dec 16, 2024

Jul 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024

Sep 16, 2024

Oct 07, 2024

Sep 16, 2024

May 29, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024

Jun 17, 2024

Jul 08, 2024

Jun 17, 2024

Jan 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Apr 05, 2024

Mar 14, 2024

Nov 28, 2023

MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023

Dec 15, 2023

Jan 08, 2024

Dec 14, 2023

Jul 25, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Oct 06, 2023

Sep 14, 2023

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Merck & Co Inc的前五大股東是誰？



Merck & Co Inc的前五大股東如下：
The Vanguard Group, Inc.
持有股份：251.75M
佔總股份比例：10.08%。
BlackRock Institutional Trust Company, N.A.
持有股份：142.78M
佔總股份比例：5.72%。
State Street Investment Management (US)
持有股份：118.49M
佔總股份比例：4.74%。
Wellington Management Company, LLP
持有股份：76.86M
佔總股份比例：3.08%。
Geode Capital Management, L.L.C.
持有股份：58.95M
佔總股份比例：2.36%。